Antibody response after first and second-dose of ChAdOx1-nCOV (Covishield<sup>TM</sup>®) and BBV-152 (Covaxin<sup>TM</sup>®) among health care workers in India: The final results of cross-sectional coronavirus vaccine-induced antibody titre (COVAT) study.

Vaccine · 2021 · PMC8461292 · PMID 34600747

Europe PMC DOI

hedged sentence

0.1100

closest p · 2.2× alpha

0.1100

boldest claim

The sentences

did not reach statistical significancep = 0.11not close (p > 0.1)

Although Covishield recipients also reported a higher incidence of mild to moderate side-effects in 18.1% (77/425) compared to 11.1% (10/90) in Covaxin recipients after the second dose of vaccine, it did not reach statistical significance (p = 0.11).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.